U.S. markets closed

Bayer Aktiengesellschaft (BAYRY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
15.19-0.18 (-1.17%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.37
Open15.26
Bid0.00 x 0
Ask0.00 x 0
Day's Range15.15 - 15.27
52 Week Range11.65 - 21.05
Volume377,756
Avg. Volume388,925
Market Cap59.692B
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-2.99
Earnings DateN/A
Forward Dividend & Yield0.59 (3.80%)
Ex-Dividend DateApr 28, 2021
1y Target Est17.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment
    Zacks

    Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment

    Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.

  • Youth Ag Summit: Empowering the Next Generation
    News Direct

    Youth Ag Summit: Empowering the Next Generation

    Today, our planet faces the challenge of using fewer natural resources while feeding a growing population — predicted to reach almost 10 billion by 2050. The day-to-day realities of farming, agricu...

  • Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials
    Benzinga

    Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials

    Bayer AG’s (OTC: BAYRY) Parkinson’s disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative movement disorder is recruiting patients. Bayer’s subsidiary BlueRock Therapeutics’s trial will eventually enroll 10 participants. Patients will have dopamine-producing cells surgically implanted into a part of the brain called the putamen. The trial will primarily examine the safety and tolerability of DA01 cell transplantation a year after the pro